Navigation Links
American Oriental Bioengineering Announces the Inclusion of 158 Drugs in China's National Insurance Catalog
Date:12/18/2009

NEW YORK, Dec. 18 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced that 158 of the Company's drugs have been included in China's National (Medical) Insurance Catalog (the "2009 NIC"). Of these, 82 are categorized as Class A drugs and 76 are categorized as Class B drugs. Most importantly, Jinji Capsule, AOBO's best selling national branded product, has been added to the 2009 NIC since its last publication in 2004.

The 2009 NIC was released by China's Ministry of Human Resources and Social Security on November 30, 2009 as part of China's healthcare reform. According to the Chinese government, ninety percent of China's citizens will be covered by a universal healthcare system by the end of calendar 2010. As China's official drug reimbursement list, the 2009 NIC features 2,151 drugs, which are categorized as Class A (fully covered) or B (partially covered). All drugs are classified into three categories: 1) Western Chemical Drugs (349A+791B); 2) modernized Traditional Chinese Medicine (TCM) (154A+833B); and 3) TCM decoction pieces. The implementation of the plan is required immediately for Class A drugs and by 3/31/10 for Class B drugs.

Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, commented, "We are very honored that a total of 158 drugs produced by our five subsidiaries have been included in China's National Insurance Catalog. Of these, 82 products are fully reimburseable as Class A drugs and 76 qualify for partial reimbursement as Class B drugs. We are especially pleased about the inclusion of our best-performing and flagship women's health product, Jinji Capsule, in the NIC. Jinji Capsule is a widely recognized product to treat gynecological inflammation, including endometritis, annexitis and pelvic inflammations. Based on government data, 147 million women in China suffer from gynecological inflammation, and we believe that partial reimbursement for this drug will boost sales of Jinji Capsule nationwide."

Mr. Liu continued, "The 2009 NIC is a vital guideline for the expanding universal healthcare system, which aims to cover the vast majority of the population. The NIC will be fully implemented in 2010, making more drugs affordable and greatly expanding the addressable pharmaceutical market in China. We believe that the inclusion of our products in the NIC, in addition to further increasing brand recognition, will hasten our expansion into key therapeutic areas."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

SOURCE American Oriental Bioengineering, Inc.


'/>"/>
SOURCE American Oriental Bioengineering, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
4. American Oriental Bioengineering Announces Participation in September Investor Conferences
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Tips from the Journals of the American Society for Microbiology
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
10. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
11. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... N.C. (PRWEB) , ... October 09, 2017 , ... At ... announced Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, ... Stubbs was a member of the winning team for the 2015 Breakthrough Prize in ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding into ... a broad range of contract analysis services for advanced applications. Services will ...
(Date:10/6/2017)... ... 06, 2017 , ... The HealthTech Venture Network (HTVN) is ... fourth annual Conference where founders, investors, innovative practitioners and collaborators are invited to ... showcasing early stage digital health and med tech companies. , This day-long event ...
(Date:10/5/2017)... Philadelphia, PA (PRWEB) , ... October 05, 2017 , ... ... of the newest frontiers in human health. Gut Love: You Are My Future, the ... offers an artist’s perspective as it explores the human condition through the lens of ...
Breaking Biology Technology:
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):